文献速递认知障碍与痴呆脑血管病

血管紧张素II刺激型降压药与痴呆风险:PreDIVA试验事后分析

Association of Angiotensin II-Stimulating Antihypertensive Use and Dementia Risk: Post Hoc Analysis of the PreDIVA Trial.
PubMed 文献 · Neurology · 2020-11-05

该研究基于PreDIVA试验的事后分析,纳入1909名70-78岁无痴呆社区人群,比较血管紧张素II刺激型与抑制型降压药对痴呆风险的影响。中位随访6.7年,刺激型组痴呆发生率5.6%,抑制型组8.2%,校正混杂因素后刺激型组痴呆风险降低45%(HR 0.55,95%CI 0.34-0.89),支持血管紧张素假说。

要点

  • 刺激型降压药组痴呆风险较抑制型组低45%(HR 0.55),且不增加死亡风险。
  • 两组死亡率无显著差异(HR 0.86,95%CI 0.64-1.16)。
  • 结果在无心血管病史者中可能更明显,需进一步验证。

核心结论

  • 使用血管紧张素II刺激型降压药者较抑制型者痴呆发生率更低,支持血管紧张素假说。

研究设计与样本

  • PreDIVA试验事后分析,纳入1909名70-78岁无痴呆社区人群(54%女性),中位随访6.7年。

主要发现

  • 刺激型组痴呆发生率5.6%(27/480),抑制型组8.2%(59/721),兼用组6.9%(46/669)。
  • 校正痴呆风险因素后,刺激型组痴呆风险降低45%(HR 0.55,95%CI 0.34-0.89),无超额死亡(HR 0.86,95%CI 0.64-1.16)。
  • 兼用组痴呆风险非显著降低20%(HR 0.80,95%CI 0.53-1.20),无超额死亡(HR 0.97,95%CI 0.76-1.24)。

临床怎么用

  • 在老年高血压患者中选择降压药时,可考虑血管紧张素II刺激型药物可能降低痴呆风险,但需结合个体情况。

局限性

  • 存在适应证混杂可能,虽亚组分析提示未影响结果,仍需进一步研究证实。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To assess whether angiotensin II-stimulating antihypertensives (thiazides, dihydropyridine calcium channel blockers, and angiotensin I receptor blockers) convey a lower risk of incident dementia compared to angiotensin II-inhibiting antihypertensives (angiotensin-converting enzyme inhibitors, β-blockers, and nondihydropyridine calcium channel blockers), in accordance with the "angiotensin hypothesis." METHODS: We performed Cox regression analyses of incident dementia (or mortality as competing risk) during 6-8 years of follow-up in a population sample of 1,909 community-dwelling individuals (54% women) without dementia, aged 70-78 (mean 74.5 ± 2.5) years. RESULTS: After a median of 6.7 years of follow-up, dementia status was available for 1,870 (98%) and mortality for 1,904 (>99%) participants. Dementia incidence was 5.6% (27/480) in angiotensin II-stimulating, 8.2% (59/721) in angiotensin II-inhibiting, and 6.9% (46/669) in both antihypertensive type users. Adjusted for dementia risk factors including blood pressure and medical history, angiotensin II-stimulating antihypertensive users had a 45% lower incident dementia rate (hazard ratio [HR], 0.55; 95% CI, 0.34-0.89) without excess mortality (HR, 0.86; 95% CI, 0.64-1.16), and individuals using both types had a nonsignificant 20% lower dementia rate (HR, 0.80; 95% CI,0.53-1.20) without excess mortality (HR, 0.97; 95% CI, 0.76-1.24), compared to angiotensin II-inhibiting antihypertensive users. Results were consistent for subgroups based on diabetes and stroke history, but may be specific for individuals without a history of cardiovascular disease. CONCLUSIONS: Users of angiotensin II-stimulating antihypertensives had lower dementia rates compared to angiotensin II-inhibiting antihypertensive users, supporting the angiotensin hypothesis. Confounding by indication must be examined further, although subanalyses suggest this did not influence results. If replicated, dementia prevention could become a compelling indication for older individuals receiving antihypertensive treatment.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. van Dalen JW, Marcum ZA, Gray SL, et al. Association of Angiotensin II-Stimulating Antihypertensive Use and Dementia Risk: Post Hoc Analysis of the PreDIVA Trial. Neurology. 2020. PMID: 33154085. doi:10.1212/WNL.0000000000010996

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。